Interleukin-1 antagonism on cortisol levels in individuals with obesity: A randomized clinical trial

Fahim Ebrahimi¹,²*, Sandrine A. Urwyler¹,²*, Philipp Schuetz³,², Beat Mueller³,², Luca Bernasconi⁴, Peter Neyer⁴, Marc Y. Donath¹,², and Mirjam Christ-Crain¹,²¥

* Equally contributing first authors

¹ Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Basel Hospital, Basel, Switzerland.
² Department of Clinical Research, University of Basel Hospital, Basel, Switzerland.
³ University Department of Medicine & Division of Endocrinology, Diabetes and Metabolism, Kantonsspital Aarau, Aarau, Switzerland.
⁴ Department of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland.

Short title: Effects of IL-1 antagonism on cortisol levels in individuals with obesity

ClinicalTrials.gov Identifier: NCT02672592

Total word count: 2529

¥Corresponding author:
Mirjam Christ-Crain, MD PhD
Endocrinology, Diabetes and Metabolism
University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
Phone: +41 (61) 328 70 80
Fax: +41 (61) 265 51 00
E-Mail: mirjam.christ@usb.ch

E-Mail addresses:
Fahim Ebrahimi f.ebrahimi@outlook.com
Sandrine A. Urwyler sandrine.urwyler@usb.ch
Luca Bernasconi luca.bernasconi@ksa.ch
Peter Neyer peter.neyer@ksa.ch
Philipp Schuetz schuetzph@gmail.com
Beat Mueller happy.mueller@unibas.ch
Marc Y. Donath marc.donath@usb.ch
Mirjam Christ-Crain mirjam.christ@usb.ch

Disclosure Statement: FE, SU, LB, PN, PS, BM, and MCC have nothing to declare. MD is an inventor on patent WO 2004002512 A1.

Keywords: Metabolic syndrome, inflammation, interleukin-1, HPA axis, anakinra
Abstract

BACKGROUND Anti-inflammatory treatment with Interleukin-1 (IL-1) antagonism decreases both cortisol and adrenocorticotropic hormone (ACTH) levels in individuals with obesity in short-term. However, it remains unknown whether these effects persist upon prolonged treatment.

METHODS In this double-blind, parallel-group trial involving patients with features of the metabolic syndrome, 33 patients were randomly assigned to receive 100 mg of anakinra (recombinant human IL-1 receptor antagonist) subcutaneously twice daily and 34 patients to receive placebo for 4 weeks. For this analysis change in cortisol and ACTH levels from baseline to 4 weeks were predefined end-points of the trial.

RESULTS The mean age was 54 years, baseline cortisol levels were 314 nmol/L (IQR 241 to 385) and c-reactive protein (CRP) levels were 3.4 mg/L (IQR 1.7 to 4.8). Treatment with anakinra led to a significant decrease in cortisol levels at day 1 when compared to placebo with an adjusted between-group difference of 28 nmol/L (95% CI, (-7) to (-43); \(P=0.03\)). After 4 weeks the cortisol-lowering effect of anakinra was attenuated and overall was statistically not significant (\(P=0.72\)). Injection-site reactions occurred in 21 patients receiving anakinra and were associated with higher CRP and cortisol levels.

CONCLUSIONS IL-1 antagonism decreases cortisol levels in male patients with obesity and chronic low-grade inflammation on the short-term. After prolonged treatment, this effect is attenuated, probably due to injection-site reactions. (ClinicalTrials.gov, NCT02672592.)
Introduction

Obesity is a pandemic, associated with high morbidity and mortality, particularly due to the onset and progression of metabolic comorbidities such as hypertension, dyslipidemia, and diabetes mellitus (1, 2). A key pathogenic pathway in the development of metabolic complications and atherosclerosis is the release of pro-inflammatory cytokines from adipose tissue promoting a state of chronic low-grade inflammation (3, 4, 5). It has been suggested that inflammation in turn leads to an increased activity of the hypothalamus-pituitary-adrenal (HPA) axis with excess of glucocorticoids which are known to increase the risk for metabolic complications and cardiovascular mortality (6).

Interleukin-1β (IL-1β) is known to potently stimulate hypercortisolism (7, 8), since it has shown to interact at all levels of the HPA axis: first, on the hypothalamus due to the co-localization of IL-1 and corticotropin releasing hormone (CRH) producing cells (9, 10), second on adrenocorticotropic hormone (ACTH)-producing cells in the pituitary gland (7) and third in the adrenal glands with direct stimulatory effect on cortisol production (11).

Therapeutic interventions aimed at counteracting inflammatory activation have proven potential to improve both glycemic control (12) and prevent cardiovascular complications (13). Recently, the large randomized controlled CANTOS trial demonstrated that antagonism of the IL-1 inflammatory pathway significantly reduced major adverse cardiovascular event rates in patients with chronic low-grade inflammation (13). These highly beneficial effects of such anti-inflammatory treatment on metabolism and atherosclerosis may to some extent be explained by a reduction of cortisol excess. We recently reported that short-term IL-1
antagonism has the capacity to decrease ACTH, serum cortisol and salivary cortisol levels in individuals with obesity and features of the metabolic syndrome (14). The aim of the current randomized, placebo-controlled study was to investigate whether these effects on the HPA axis persist upon prolonged IL-1 receptor antagonism.

Methods

Study design
This is a secondary analysis of a placebo-controlled, double-blind, randomized intervention trial which was conducted at two tertiary care centers in Switzerland involving middle-aged men with obesity and features of metabolic syndrome and moderately low levels of total testosterone. The primary aim of the study was to investigate the effects of interleukin-1 antagonism on the hypothalamus-pituitary gonadal axis (15). A predefined secondary aim was to investigate the effect of a 4-week treatment on serum cortisol levels. Patients were recruited from January 2016 to June 2017 and received either twice-daily recombinant human interleukin-1–receptor antagonist (200 mg of anakinra [Kineret®] per day) or placebo for 4 weeks. Efficacy was assessed at baseline, after 1 day, 4 weeks and 3 months. Data on adverse events were collected during the treatment period and for 2 months thereafter.

Participants received a set of study medication, which was prepared prior to the initiation of the study and packed by the Hospital Pharmacy, University Hospital Basel, which was responsible for blinding procedures and randomization.
Patients
The trial was conducted according to the declaration of Helsinki and Good Clinical Practice Guidelines. The study was approved by the Ethics Committee northwest/central Switzerland (EKNZ) prior to patient recruitment and the trial was registered on ClinicalTrials.gov (clinicaltrials.gov ID: NCT02672592).

Main eligibility criteria were men aged 18 to 75 years with a body-mass index (BMI) of more than 30 kg/m², a morning total testosterone levels below 12 nmol/L, and at least one of the following additional parameters of the metabolic syndrome: hyperglycemia (glycated hemoglobin more than 5.7% or 39 mmol/mol), hypertension (blood pressure more than 130/85 mmHg or treatment for hypertension), or dyslipidemia (high density lipoprotein [HDL] lower than 1.0 mmol/L, triglycerides higher than 1.7 mmol/L, low density lipoprotein [LDL] higher than 3.4 mmol/L, or lipid lowering treatment). The trial excluded from enrollment with drug abuse, infection during the last 2 months, or an immunocompromised state. Complete inclusion and exclusion criteria have been published recently (15).

Study Procedures
All patients provided written informed consent. Eligible patients were randomly assigned (1:1 ratio) to receive 100 mg of the recombinant human interleukin-1 receptor antagonist anakinra, purchased by Swedish Orphan Biovitrum, or an identically appearing placebo twice-daily, as self-administered, subcutaneous injections for 4 weeks. Compliance to treatment was assessed by counting returned empty syringes, by keeping a medication diary and by measurement of plasma interleukin-1 receptor antagonist concentrations at 4 weeks.
At a screening visit, an investigator collected medical history, performed physical examination and a blood sampling. The study procedures have been reported in detail previously (15).

**Laboratory measurements**

Routine clinical laboratory tests were performed locally at both participating centers. Serum samples were stored at ~80°C. C-reactive protein (CRP) was determined with an immunoturbidimetric assay (Tina-quant C-reactive Protein Gen. 3 Test, Roche Diagnostics GmbH, Mannheim, Germany). ACTH was quantified with a chemiluminescence immunoassay (ACTH Immulite, Siemens Healthcare Diagnostics Products Ltd., Gwynedd, UK), with a reference range <46.0 pg/mL. Serum total cortisol was measured using a commercially available and certified liquid chromatography tandem mass spectrometry (LC-MS/MS) assay (MassChrom Steroids; Chromsystems, Munich, Germany). The analyses were performed using an UltiMate 3000 ultra-high-performance liquid chromatography (UHPLC) system (Thermo Fisher Scientific, San Jose, CA, USA) coupled to an AB Sciex 5500 QTRAP quadrupole mass spectrometer (AB Sciex, Darmstadt, Germany). The Turbo V ion source (AB Sciex) was operated in positive electrospray ionization mode. The targeted screening method employed the multiple reaction monitoring mode of operation using two transitions for each analysis sample and two for the internal standard. Prior to injection into the UHPLC system, serum samples were subjected to a complex process of reversed phase 96-well solid-phase extraction, purification, and concentration as described in the MassChrom Steroids user’s manual.
According to the manufacturer’s manual, the lower limit of quantitation was 4 nmol/L, and linear range 4 to 1656 nmol/L. The relative recovery was calculated by adding known amounts of cortisol to serum samples and analyzing by LC-MS/MS and amounted to 102±3%. There is no measurable carryover effect on the blank after running the highest standard (810 nmol/L). The interassay coefficient of variation is 2.6% at 71 nmol/L, 2.1% at 170 nmol/L, and 3.6% at 494 nmol/L, respectively.

**Statistical analysis**
Discrete variables are expressed as counts (percentage) and continuous variables as medians (interquartile range [IQR]) unless stated otherwise. Frequency comparisons were made with the chi-square test. We used a linear regression (ANCOVA) model adjusted for the baseline value of the dependent variable to investigate changes in cortisol levels and other secondary outcomes. For linear regression analyses cortisol levels were log-transformed in order to achieve normal distribution. Multivariate analyses were performed adjusting for age, BMI, c-reactive protein, and occurrence of injection-site reactions. Changes within each group were tested with the use of a paired t-test or with Wilcoxon signed rank test in case of non-normal distribution. Predefined subgroup analyses were performed based on baseline CRP levels of less than or equal to or greater than 2 mg/L; baseline BMI of less than or equal to or greater than 40 kg/m², baseline total testosterone levels of less than or equal to or greater than 8 nmol/L, on the basis of the occurrence of injection-site reactions, or on the basis of achieving on-treatment reductions in CRP at 1 week of less than or equal to or greater than 1 mg/L. All P-values are two-sided and all CIs are at the 95% level. There was no
Results

Patient characteristics
In total, 67 patients were included in the study, of whom all were male. Clinical and demographic baseline characteristics were well balanced between randomized groups (Table 1). The median age was 55 years, median BMI was 37 kg/m² (interquartile range (IQR) 34 to 39), and more than half of the patients were either prediabetic (19/67) or had type 2 diabetes mellitus (16/67) resulting in a median HbA1c of 5.8% (IQR 5.4 to 6.3). Further metabolic features were prevalent with 47 out of 67 patients suffering from hypertension and 57 patients from dyslipidemia. Morning fasting cortisol levels at baseline were 314 nmol/L (IQR 241 to 385) and median c-reactive protein (CRP) levels were 3.4 mg/L (IQR 1.7 to 4.8), mirroring a state of chronic low-grade inflammation.

Effects of IL-1 antagonism on the HPA axis
In patients allocated to anakinra, cortisol levels at baseline were 329 nmol/L (IQR 267 to 382) and decreased by -16 nmol/L (IQR (-87) to 77) after 1 day of treatment. In comparison, patients receiving placebo had a baseline level of 293 nmol/l (IQR 231 to 387) and a median increase by 2 nmol/L (IQR (-51) to 46) at day 1. There was a mean adjusted between-group difference of -28 nmol/L (95% confidence interval [CI], (-7) to (-43); P= 0.03) (Figure 1). However, at 4 weeks this effect was no longer visible. Over the treatment period of 28 days, in both groups cortisol levels increased when compared to baseline. In the anakinra group
cortisol levels increased by 18 nmol/L (IQR (-43) to 93), as compared to an increase of 31 nmol/L (IQR (-29) to 95) in the placebo group, yielding a non-significant between-group difference of -18 nmol/L (95% CI, (-71) to 36; P=0.72).

At 3-months follow-up visit there was likewise no significant difference in cortisol levels between anakinra and placebo group (between group difference 20 nmol/L; 95% CI (-40) to 81; P= 0.50). There was no effect on ACTH levels at any time point (P>0.05). Likewise, over the 4-week period there was no effect on fasting glucose levels.

**Changes in cortisol among pre-defined subgroups**

When the patients were stratified into two pre-defined groups according to baseline inflammatory state (CRP ≥2 mg/L versus <2 mg/L), there was no significant between-group difference at any time point (P>0.05). The proportions of individuals achieving on-treatment CRP reductions of more than 1 mg/L at 1 week were 3 out of 34 (9%) in the placebo group and 25 out of 33 (76%) in the anakinra group. Compared with placebo, participants allocated to anakinra who had CRP concentrations of more than 1 mg/L tended to having more pronounced reductions in cortisol levels of -24 nmol/L (95% CI, (-184) to 136; P=0.77), although the difference did not attain statistical significance. A decrease in the change of CRP tended to correlate with a decrease in cortisol levels (day 1: R^2= 0.198, P= 0.077) (Figure S1 Supplemental Material). Patients with a BMI at baseline of equal to or greater than 40 kg/m^2 tended to having a more pronounced reduction in cortisol levels by -68 nmol/L (95% CI, (-197) to 59) compared to patients with BMI below 40 kg/m^2. However, there was no statistical significance between the groups (P=0.29). Though, men with baseline total testosterone levels higher than 8 nmol/L
tended to having a more pronounced short-term decrease in cortisol levels upon anakinra treatment (between group difference -63 nmol/L; 95% CI (-125) to (-0.02); $P= 0.047$). However, similar to the total cohort the observed effect on cortisol was no longer evident at 4 weeks (between group difference -22 nmol/L; 95% CI (-137) to 93; $P= 0.71$). Baseline testosterone levels were not correlated with changes in cortisol (day 1: $R^2= 0.048$, $P= 0.22$; 4 weeks: $R^2= 0.033$, $P= 0.31$).

During the quite short study period there were no cardiovascular adverse events. In 21 out of 33 patients receiving anakinra developed injection-site reactions, compared to no skin reactions in the placebo group ($P < 0.001$). In the anakinra group, patients who developed injection-site reactions had higher c-reactive protein levels at 4 weeks by 0.9 mg/L (95% CI (-2.8) to 4.7) compared to patients receiving anakinra but not developing skin reactions. However these changes between the groups did not attain statistically significant and therefore are exploratory (Figure 2A). Similarly, at 4 weeks cortisol levels tended to be higher by 35 nmol/L (95% CI -43 to 113) in patients suffering from injection-site reactions compared to those with no skin reactions, however changes did not meet statistical significance and are exploratory (Figure 2B).
Discussion

This randomized, double blind placebo-controlled trial of IL-1 antagonism affirmed that anti-inflammatory treatment with anakinra leads to a reduction in cortisol levels in individuals with obesity and features of the metabolic syndrome on the short-term, however with no significant effect after prolonged treatment.

Increased levels of cortisol have been associated with excess morbidity and mortality in the metabolic syndrome. Hypercortisolemia as seen in Cushing’s syndrome has been known to be associated with metabolic dysregulation, development of diabetes mellitus and massive increase in cardiovascular risk profiles (16, 17).

Recently, the large Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) which enrolled more than ten thousand patients with low-grade chronic inflammation, showed significantly reduced major adverse cardiovascular event rates, when targeting the interleukin-1β inflammatory pathway (13). However, the underlying mechanisms leading to the outcome benefit for cardiovascular events as well as all-cause mortality are still matter of debate. In the current trial, we did not observe effects of anakinra on lipid levels when compared with placebo (15). This finding is in accordance with data from the CANTOS trial which showed that incidence of recurrent cardiovascular events was significantly reduced upon IL-1 inhibition, without any effects on LDL, HDL, and triglyceride levels, respectively (13). This has led to the assumption that significant improvements in metabolism may have directly contributed to the reduced mortality aside from direct protective effects on vascular endothelium (18, 19, 20, 21). Furthermore, in our trial, patients
allocated to anakinra tended to have a blood-pressure lowering effect on both systolic and diastolic blood pressure, by -3.1 mmHg and -2.7 mmHg, respectively. Heart rate was not affected (15).

IL-1 antagonism has been shown to improve glycemia via improved beta-cell secretory function (12) in patients with obesity and metabolic syndrome. However, the current trial was not designed and not powered to investigate effects on glucose metabolism, since most of included patients did not have impaired glucose tolerance (only 16 (24%) patients were diabetic, hence already at baseline HbA1c levels were rather low with a median of 5.8% (interquartile range [IQR] 5.4, 6.3) (Table 1).

These beneficial effects on metabolism have been related to be at least in part due to a reduction in cortisol levels (14). In fact, short-term treatment with anakinra significantly decreased both serum and salivary cortisol levels which was accompanied by significant reduction in ACTH levels, providing a possible additional mechanism for the reduction in cardiovascular risk. In the current randomized controlled trial, we show that this effect on cortisol levels is primarily short-term without a significant difference compared to placebo after 4 weeks.

However, circulating levels of cortisol may not fully reflect metabolic effects of IL-1 antagonism, since intracellular determinants of cortisol metabolism and action need as well to be taken into consideration. In this context, regulation of the local expression of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) in adipose tissue appears to be a major factor. Adipose 11β-HSD1 is the key enzyme catalyzing the conversion of inactive cortisone into the hormonally active cortisol.
In fact, previous studies have shown that individuals with obesity and metabolic syndrome have an overexpression of 11β-HSD1 in adipocytes resulting in increased conversion of cortisone to cortisol and consequently in excessive tissue-specific glucocorticoid activity (24). In fact, locally acting adipocyte-derived IL-1β has been shown to be one major factor stimulating the transcriptional activity and overexpression of the 11β-HSD1 gene (25, 26). Against this background, beneficial effects of IL-1-antagonism on insulin resistance and glucose metabolism may therefore not fully be explained by an inhibition of HPA-axis and consequent reduction of circulating levels of cortisol. It is worth investigating whether the beneficial metabolic effects may at least to some be explained through down-regulation of the transcriptional activity of 11β-HSD1 within adipose tissue and thereby reduced tissue-specific concentrations of glucocorticoids.

Compared to previous studies using anakinra in cardiovascular diseases (27), higher doses were used in our trial, based on previous clinical data indicating reduced efficacy of anakinra with higher body surface area in obese patients (12). Although pro-inflammatory states have been associated with higher circulating levels of IL-1 receptor antagonist (28), this is rather counterregulatory and does not mirror a pro-inflammatory action. For this reason we do not assume that the higher dose used in our study may have limited the efficacy of anakinra. Though, a possible explanation for the less pronounced effects on circulating levels of cortisol at 4 weeks are injection-site reactions which were relatively frequent in our study, presumably due to the higher dose of anakinra. This observation is consistent with previous studies indicating a dose-escalating incidence and severity of injection-site reactions (29, 30). We found diminished effects on cortisol levels in patients
who developed skin reactions; this phenomenon has been described as well in earlier studies with anakinra (31) and may be due to an inflammatory reaction in the subcutaneous tissue (29). Another possible explanation of the effect attenuation with prolonged anti-inflammatory treatment might be a counterregulatory stimulatory effect of other cytokines on the HPA-axis. Interleukin-6, Tumor-necrosis factor-α (TNF-α) and IL-10 derive from the visceral adipose tissue or are produced in the hypothalamus and are known to stimulate the HPA-axis. Possibly, as a mechanism of compensation after the long-term blocking effects of IL-1, the stimulation via these alternative pathways might flare up and result in an re-upregulation of the HPA-activity reflected by the re-increase in cortisol levels (32, 33, 34, 35).

The following limitations need to be considered. First, inclusion of patients with only marginal systemic inflammation may have underestimated the overall effects of IL-1 antagonism on metabolism. Second, this is a secondary analysis and the original study was not powered to find a difference in cortisol levels. Third, the TestIL study was only performed in caucasian men at two sites in Switzerland, so it is unclear whether these results can be extrapolated to individuals from other races, sex, or countries. However, strengths of our study include the randomized, controlled and double-blind design, the high accuracy and reproducibility of the measurement methods, and correlation of laboratory effects with clinical variables.

In conclusion, these data contribute to the understanding of the interplay between obesity, increased activity in the HPA axis, and development of metabolic complications. However, larger and longer term studies with anti-inflammatory therapy are warranted to analyze additional mediators in this relationship and to
further examine the hypothesis that beneficial effects of IL-1 antagonism on metabolism and cardiovascular outcome may at least to some extent be explained by a reduced activity of HPA axis and diminished tissue-specific cortisol action.

Financial Support

MCC received a grant of the Swiss National Foundation (Nr PP00P3-12346), FE was supported by the "Wissenschaftspool" of the University Hospital Basel, a grant of the University of Basel (Nachwuchsfoerderung 2017), and through the «Young Talents in Clinical Research» program by the Bangerter Foundation and the Swiss Academy of Medical Sciences (SAMS). The funding sources were neither involved in the design of the study nor in writing of the manuscript.

Conflicts of interest

MD is listed as the inventor on a patent filed in 2003 for the use of an interleukin-1–receptor antagonist for the treatment of or prophylaxis against type 2 diabetes.

Acknowledgments

We gratefully thank Nina Hutter and Cemile Bathelt for excellent assistance at study visits and Christoph Saxer for technical assistance for laboratory analyses.
Ebrahimi and Urwyler et al. 2019

Figure Legends

**Figure 1 Effects of anakinra on serum cortisol levels.**
Median absolute differences in cortisol levels between the baseline value and measurements at day 1 and at end of the 4-week study period. The error bars indicate standard errors.

**Figure 2. Injection-site reactions and cortisol levels.**
Panel A shows the average absolute differences in C-reactive protein levels between the baseline value and measurements at day 1 and 28 during the 4-week study period. Panel B shows the average absolute difference in cortisol levels at day 1 in each study group stratified by occurrence of injection-site reactions. Injection-site reactions emerged in 21 out of 33 patients receiving anakinra, compared to no patients in the placebo group. These analyses are exploratory, showing distinct trends, although the difference did not attain statistical significance.
References


### Tables

#### Table 1 - Baseline characteristics and clinical variables of enrolled patients

<table>
<thead>
<tr>
<th>Characteristic/variable</th>
<th>Total (N=67)</th>
<th>Placebo (N=34)</th>
<th>Anakinra (N=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General characteristics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>55 (44, 65)</td>
<td>55 (43, 65)</td>
<td>55 (45, 67)</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>113 (104, 124)</td>
<td>114 (102, 124)</td>
<td>113 (107, 122)</td>
</tr>
<tr>
<td>Body mass index (kg/m$^2$)</td>
<td>37 (34, 39)</td>
<td>36 (34, 40)</td>
<td>37 (34, 39)</td>
</tr>
<tr>
<td>&lt;35</td>
<td>21/67</td>
<td>11/34</td>
<td>10/33</td>
</tr>
<tr>
<td>35-40</td>
<td>35/67</td>
<td>18/34</td>
<td>17/33</td>
</tr>
<tr>
<td>&gt;40</td>
<td>11/67</td>
<td>5/34</td>
<td>6/33</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>123 (117, 132)</td>
<td>123 (116, 134)</td>
<td>124 (119, 131)</td>
</tr>
<tr>
<td>Body surface area (m$^2$)</td>
<td>2.4 (2.2, 2.5)</td>
<td>2.4 (2.2, 2.5)</td>
<td>2.3 (2.2, 2.5)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>133 (126, 142)</td>
<td>132 (123, 139)</td>
<td>136 (130, 147)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>88.7 (80.0, 93.0)</td>
<td>85.3 (78.3, 94.0)</td>
<td>89.7 (83.7, 92.7)</td>
</tr>
<tr>
<td>Gynaecomastia</td>
<td>36/67</td>
<td>17/34</td>
<td>19/33</td>
</tr>
</tbody>
</table>

#### Comorbidities

<table>
<thead>
<tr>
<th>Condition</th>
<th>Total (N=67)</th>
<th>Placebo (N=34)</th>
<th>Anakinra (N=33)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prediabetes</td>
<td>19/67</td>
<td>9/34</td>
<td>10/33</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>16/67</td>
<td>7/34</td>
<td>9/33</td>
</tr>
<tr>
<td>Diet</td>
<td>1/16</td>
<td>0/7</td>
<td>1/9</td>
</tr>
<tr>
<td>Oral drug</td>
<td>14/16</td>
<td>6/7</td>
<td>8/9</td>
</tr>
<tr>
<td>Insulin (alone or with oral drug)</td>
<td>1/16</td>
<td>1/7</td>
<td>0/9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>47/67</td>
<td>21/34</td>
<td>26/33</td>
</tr>
<tr>
<td>Use of antihypertensive medication</td>
<td>30/47</td>
<td>14/21</td>
<td>16/26</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>57/67</td>
<td>29/34</td>
<td>28/33</td>
</tr>
<tr>
<td>Statin treatment</td>
<td>18/57</td>
<td>7/29</td>
<td>11/28</td>
</tr>
</tbody>
</table>

Copyright © 2019 the authors
Obstructive sleep apnea | 21/67 | 7/34 | 14/33
CPAP treatment | 14/21 | 5/7 | 9/14
Smoking status
   former | 26/67 | 14/34 | 12/33
   current | 16/67 | 5/34 | 11/33
Packyears | 20 (10, 30) | 20 (10, 30) | 20 (10, 36)
Psychiatric disease | 7/67 | 3/34 | 4/33

**Laboratory values**

<table>
<thead>
<tr>
<th>Test</th>
<th>Median (IQR)</th>
<th>Median (IQR)</th>
<th>Median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c (%)</td>
<td>5.8 (5.4, 6.3)</td>
<td>5.8 (5.4, 6.1)</td>
<td>5.9 (5.5, 6.3)</td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
<td>5.6 (5.1, 6.7)</td>
<td>5.5 (5.1, 6.2)</td>
<td>5.8 (5.2, 7.8)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.8 (3.8, 5.7)</td>
<td>4.7 (4.0, 5.5)</td>
<td>5.3 (3.8, 5.7)</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.9 (2.1, 3.8)</td>
<td>2.8 (2.1, 3.8)</td>
<td>3.1 (1.8, 4.0)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.1 (1.0, 1.3)</td>
<td>1.1 (1.0, 1.3)</td>
<td>1.2 (1.0, 1.3)</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.7 (1.3, 2.6)</td>
<td>1.8 (1.2, 2.6)</td>
<td>1.7 (1.3, 2.6)</td>
</tr>
<tr>
<td>Cortisol (nmol/L)</td>
<td>314 (241, 385)</td>
<td>293 (231, 387)</td>
<td>328 (267, 382)</td>
</tr>
<tr>
<td>Adrenocorticotrope hormone (pg/mL)</td>
<td>23 (17, 32)</td>
<td>23 (16, 33)</td>
<td>24 (20, 32)</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>3.4 (1.7, 4.8)</td>
<td>3.6 (1.6, 4.9)</td>
<td>3.2 (2.1, 4.5)</td>
</tr>
<tr>
<td>Interleukin-6 (pg/mL)</td>
<td>2.3 (2.0, 3.7)</td>
<td>2.2 (2.0, 3.9)</td>
<td>2.6 (2.0, 3.6)</td>
</tr>
</tbody>
</table>

Data are presented as median (IQR) or fractions n/total. The body-mass index is the weight in kilograms divided by the square of the height in meters. Gynaecomastia was not confirmed by ultrasonography and thus not differentiated from pseudogynaecomastia.
Median absolute differences in cortisol levels between the baseline value and measurements at day 1 and at end of the 4-week study period. The error bars indicate standard errors.

P=0.03

Copyright © 2019 the authors
Panel A shows the average absolute differences in c-reactive protein levels between the baseline value and measurements at day 1 and 28 during the 4-week study period. Panel B shows the average absolute difference in cortisol levels at day 1 in each study group stratified by occurrence of injection-site reactions. Injection-site reactions emerged in 21 out of 33 patients receiving anakinra, compared to no patients in the placebo group. These analyses are exploratory, showing distinct trends, although the difference did not attain statistical significance.

224x378mm (300 x 300 DPI)